Treace Medical Q2 revenue $30M (+45% YoY); raises FY22 guidance to $130-134M; net loss widens to $17.2M

TREACE MEDICAL CONCEPTS, INC.

2022-Q2 EPS reported -$0.48 revenue$59,014,000

Revenue $30M, +45% YoY; gross margin 81.1% (+20 bps). Direct channel 68% of sales vs 51% prior year.
Net loss attributable to common $17.2M ($0.31/share) vs $5.1M loss prior year; adjusted net loss $12.8M ($0.23/share).
Adjusted EBITDA loss $9.4M vs $3.1M loss prior year; operating expenses increased to $36.2M from $20.7M.
Raises FY2022 revenue guidance to $130-134M (38-42% growth) from prior $128-133M.
Ended Q2 with $101.5M cash; new $150M loan arrangement provides liquidity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.